REDPEVA

Regional Meeting of National Programs for Venomous Animals Accidents in Latin America and the Caribbean

São Paulo, Brazil | 21-22 August 2025

Strategic Fund's role in antivenoms access

Dr. Christopher Lim Chief, Strategic Fund











Strategic Fund

The RRFs are technical cooperation mechanisms that enable the Americas to equitable access timely quality vaccines, essential medicines, and public health supplies.

Through pooled procurement,
Member States obtain affordable
prices and plan their demand
together to obtain benefits for all plus,
a reliable demand predictability.










Regional Revolving Funds Achievements in 2024













Comparative advantages of Regional Revolving Funds



Single access for demand consolidation and economies of scale.



Guaranteed quality for MS and technical support facilitator beyond the purchase process and throughout the useful life of the supply.



Timely financing through its line of credit.



Serve as process facilitator and provide technical support for efficient planning, financial projections, shipment monitoring, and market analysis.



Transparency in processes and prices.









Regional Revolving Funds Portfolio



Treatment

equipment



Vaccines and related supplies

Communicable Diseases

Non-Communicable Diseases

Neglected Diseases

High-Price Medicines

Antivenoms

Rapid tests

Diagnostic kits

and medical

Equipment and supplies

Tests for syphilis, Hepatitis, HPV, o.i., c.v. y CD4

Telehealth

Insecticides

Long-lasting mosquito nets

Vaccines

Syringes and safety boxes

Immunoglobulins

Cold boxes










Strategic Fund: Demand received in 2025



On hold: Argentina Ecuador Peru Paraguay Uruguay













Lessons learned from Communicable and Non-Communicable diseases initiatives



Centralized and pooled procurement increases supply security and reduces costs



Standardized treatment guidelines and product specifications are essential



Demand and Supply Chain planning and visibility



Regional regulatory pathways, harmonization, and reliance









Quality assurance through the Strategic Fund



WHO-prequalified products



Eligible if products have been prequalified by WHO before opening bids.

Non-prequalified products by WHO

Authorized by:

1.Stringent Regulatory Authorities (SRAs)** recognized by WHO


2.PAHO/WHO's National Regulatory Authorities of Regional Reference*















Challenges for access and availability of antivenoms

Irregular supply of antivenoms /
Lack of a strategic minimum stock

4 Lack of visibility of regional demand

Suppliers that do not meet the eligibility criteria for inclusion in the SF portfolio

Supply depends on donations from PAHO in emergency situations and/or producing countries.

Long production lead time of 6-8 months





Interprogrammatic actions developed

- List of antivenoms required to be included in the Strategic Fund List
- Definition of pharmaceutical presentations of the 32 requested antivenoms
- Evaluation of the antivenoms to be included in the Strategic Fund
 - Classification by species and products required by country/subregion
- Identification and mapping of products and private and public producers in the region











Our call to action



- Identify the demand for antivenoms by subregion and collaborate with potential laboratories.
- Define users within the Member States Portal.
- Develop international tender processes
- Promote joint regional procurement



Medium term

 Strengthen local production and logistics capabilities.







REDPEVA

Regional Meeting of National Programs for Venomous Animals Accidents in Latin America and the Caribbean

São Paulo, Brazil | 21-22 August 2025

THANK YOU

Dr. Christopher Lim Chief, Strategic Fund limchr@paho.org





